[1] CHEN LX, CHEN DC.Update and analysis of clinical diagnosis and treatment guidelines for aspergillus infection (IDSA 2016 Edition)[J].Chinese Journal of Medicine(中国医刊), 2018,53(6): 595-598. [2] Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease[R/OL].[2021-02-20].https://goldcopd.org. [3] BADDLEY JW.Clinical risk factors for invasive aspergillosis[J]. Medical Mycology, 2011, 49(Suppl 1): S7-S12. [4] BAO ZJ, XU JP, CHEN AF.Risk factors for secondary pulmonary fungal infection in patients with chronic obstructive pulmonary disease[J].Chinese Journal of Nosocomiology(中华医院感染学杂志), 2014, 24(17):4245-4247. [5] WANG C, CHI CH, CHEN RC, et al.Guideline for primary care of chronic obstructive pulmonary disease (2018)[J]. Chinese Journal of General Practitioners(中华全科医师杂志), 2018, 17(11): 856-870. [6] Working Group on Revision of Guiding Principles for Clinical Application of Antibiotics. Guiding Principles of Clinical Use of Antibiotics(2015)(抗菌药物临床应用指导原则2015年版)[M]. Beijing People’s Medical Publishing House, 2015. [7] Infection Group of Chinese Thoracic Society.Chinese Journal of Tuberculosis and Respiratory Editorial Committee.Expert consensus on diagnosis and treatment of pulmonary mycosis[J].Chinese Journal of Tuberculosis and Respiratory Diseases(中华结核和呼吸杂志), 2007, 30(11):821-834. [8] PATTERSON TF, THOMPSON GR 3RD, DENNING DW, et a1. Practice guidelines for the diagnosis and management of aspergillosis:2016 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2016, 63(4): el-e60. [9] ZONIOS D, YAMAZAKI H,MURAYAMA N, et al.Voriconazole metabolism,toxicity,and the effect of cytochrome P450 2C19 genotype[J]. J Infect Dis, 2014, 209: 1941-1948. [10] ZHANG XJ, CAI R, LAI B, et al.Study on the risk factors of voriconazole hepatotoxicity[J]. Hebei Medical Journal(河北医药), 2016, 38(4): 617-620. [11] CHEN K, ZHANG X, KE X, et al.Individalized medication of voriconazole:a practice guideline of the division of therapeutic drug monitoring, Chinese pharmacological society[J]. Ther Drug Monit, 2018, 40(6): 663-674. [12] Chinese Medical Association, Chinese Medical Association Publishing House, Chinese Society of Gastroenterology, et al. Guideline for primary care of drug-induced liver injury(2019)[J]. Chinese Journal of General Practitioners(中华全科医师杂志), 2020, 19(10):868-875. [13] ZHOU R, CHEN ZZ.Pharmacists’participation in the treatment of a patient with complicated abdominal infection secondary to invasive fungal infection[J].Chinese Journal of Pharmacovigilance(中国药物警戒), 2020,17(2): 106-110. [14] CHEN DC, FENG SZ, HU JD, et al.Multidisciplinary clinical evaluation of micafungin[J].The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2014, 30(11): 1071-1078. [15] CORNELY OA, SIDHU M, ODEYEMI I, et al.Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany[J]. Curr Med Res Opin, 2008, 24: 1743-1753. [16] NEOH CF, LIEW D, SLAVIN MA, et al.Economic evaluation of micafungin versus caspofungin for the treatment of candidaemia and invasive candidiasis[J]. Intern Med J, 2013, 43: 668-677. [17] SHU YQ, LI Y.Clinical effectiveness and utilization review of caspofungin and micafungin in treatment of in-vasive fungal infections in critical patients[J]. Practical Journal of Clinical Medicine(实用医院临床杂志), 2012, 9(5): 80-82. [18] WANG FL, JIANG T, ZHENG LL.Pulmonary coinfection by aspergillus and pneumocystis jirovecii:a case report and Literature review[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2021, 41(13): 1372-1376. [19] WANG L, GAO LJ, AN Y, et al.Diagnostic value of serum aspergillus-specific IgG and IgE in allergic bronchopulmonary aspergillosis[J].Guangxi Medical Journal(广西医学), 2020, 42(23): 3039-3042. [20] ZHANG Y, MIU Q, JIN WT, et al.Etiological dignostic value of metagenomic next-generation sequencing in chronic pulmonary aspergillosis[J]. Chinese Journal of Clinical Medicine(中国临床医学), 2020, 27(4): 563-566. |